Actively Recruiting
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Led by Jiangsu Hansoh Pharmaceutical Co., Ltd. · Updated on 2025-06-24
157
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
CONDITIONS
Official Title
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- Diagnosed with pathologically confirmed advanced solid tumors
- Have at least one target lesion assessed by RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 without deterioration within 2 weeks before first dose
- Life expectancy of at least 12 weeks
- Female subjects of childbearing potential willing to use contraception and not breastfeed from consent until 6 months after last dose
- Male subjects willing to use barrier contraception from consent until 6 months after last dose
- Female subjects must have a negative pregnancy test within 7 days before first dose or demonstrate no risk of pregnancy
- Ability to understand study procedures and sign written informed consent
You will not qualify if you...
- Received or currently receiving PARP inhibitor, B7-H4, or B7-H3-targeted therapies
- Received cytotoxic chemotherapy, investigational drugs, anti-tumor traditional Chinese medicines, or other anti-tumor drugs within 14 days before first dose or need to continue these during study
- Presence of Grade 2 or higher toxicities from prior anti-tumor therapy
- Presence of pleural or abdominal effusion requiring clinical intervention
- History of other primary malignancies
- Evidence of brain metastasis or cancerous meningitis
- Inadequate bone marrow, liver, or kidney function
- Abnormal cardiological examination
- Severe, uncontrolled, or active cardiovascular disorders
- Serious or poorly controlled diabetes or hypertension
- Significant bleeding symptoms or tendency within 1 month before first dose
- Serious infections within 4 weeks before first dose
- Systemic glucocorticoid therapy for more than 7 days within 28 days before first dose, or need for chronic glucocorticoids during study
- Acquired or congenital immunodeficiency, or history of organ transplantation
- Active infectious diseases such as hepatitis B, hepatitis C, tuberculosis, syphilis, or HIV
- Current hepatic encephalopathy, hepatorenal syndrome, or severe liver cirrhosis
- Moderate or severe lung diseases affecting lung function or drug toxicity detection
- History of severe neurological or psychiatric disorders
- Pregnant or breastfeeding women or intending to become pregnant during study
- Attenuated live vaccination within 4 weeks before first dose
- Active autoimmune disease or likely recurrence
- Gastrointestinal fistula, perforation, abscess, or intestinal obstruction symptoms within 6 months before first dose
- Unlikely to comply with study procedures or requirements
- Any condition that jeopardizes safety or interferes with study assessments as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
X
Xi Yan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here